Deals
Pfizer Nears Deal to Combine Off-Patent Drug Unit With Mylan
- Mylan would get about 40% of the combined company, people say
- Pfizer’s Michael Goettler would be CEO of the new business
This article is for subscribers only.
Pfizer Inc. plans to combine its off-patent business, which includes Lipitor cholesterol pills and male-impotence drug Viagra, with Mylan NV and form a generic drug giant, according to people familiar with the matter.
The deal, if completed, could be announced as early as Monday, said the people, who asked not to be identified because the negotiations are private. Under the potential stock deal, Mylan investors would get a little more than 40% of the new entity and Pfizer investors the rest.